BUSINESS: Fujifilm’s Cristalle Digital Mammography System ASPIRE Cristalle Receives Health Canada Medical Device License

dWeb.News Article from Daniel Webster dWeb.News

dWeb.News Article from Daniel Webster dWeb.News

by Daniel Webster, dWeb.News Publisher

The ASPIRE Cristalle with digital breast tomosynthesis (DBT) is designed to increase clinical confidence, accuracy and patient comfort

October 14, 2021 11: 51 ET | Source: FUJIFILM Holdings America Corporation

Mississauga, Ont., Canada, Oct. 14, 2021 (GLOBE NEWSWIRE) — FUJIFILM Canada Inc. announced today that the company has received Health Canada medical device license for its ASPIRE Cristalle digital mammography solution and its expansion of the partnership with Christie Innomed to offer the product with superior service in every province across the country. ASPIRE Cristalle is featured with Digital Breast Tomosynthesis (DBT) technology, also known as 3D mammography. DBT, also known as 3D mammography, is a form of advanced breast imaging that uses low dose xrays to create three-dimensional images. This allows radiologists to better see lesions that may be hidden between different layers of breast tissue.

“As a company that is steadfast in empowering clinicians to detect breast cancer at its earliest stage, we are proud to offer Fujifilm’s ASPIRE Cristalle mammography system to providers in the Canadian market with our long term partner, Christie Innomed,” said Atsushi Tateishi, Director, Medical Systems Division for FUJIFILM Canada. Annual mammograms are the best way to detect breast cancer early. An imaging facility with the right technology to detect cancerous tumors is crucial for patients. FUJIFILM Canada looks forward to expanding our relationships with hospitals and clinics to provide them with the women’s health solutions that will help increase patient comfort and advance breast health care in the community.”

Statistics from the Canadian Cancer Society indicate that breast cancer is the most common cancer among Canadian women, and is the second leading cause of death from cancer. According to the society, one in eight women will get breast cancer at some point in their lives. The stage at which the breast cancer is diagnosed can affect the patient’s chances of survival. These sad statistics highlight the importance of regular screenings for patients.

The ASPIRE Cristalle with DBT combines Fujifilm’s Hexagonal Close Pattern (HCP) capture technology and intelligent image processing to optimize dose and contrast based on individual breast composition. This results in low dose, fast acquisition of high quality images for all breast types. Patients can also experience a significant improvement in comfort due to Fujifilm’s flexible comfort paddle design. This provides gentle, even compression that adapts to patients’ curves.

“The availability and accessibility of women’s health services is a priority for the Canadian health system, and Christie Innomed has been committed to Women’s Health for the past 30 years. With our long-term partner Fujifilm, we are proud to announce this groundbreaking mammography system. It will have a significant impact on Canadian technologists and radiologists. Our mission has been to help healthcare institutions deliver the best possible care for Canadian citizens. Scott Jackson, Vice President of Medical Imaging Solutions at Christie Innomed.

Fujifilm digital radiography (DR) solutions offer clinicians workflow efficiencies while providing exceptional image quality at a low dose. Since the inception of FUJIFILM Canada Inc.’s Medical Systems Division in 2019, the company offers providers in the region with a broad range of digital radiography and women’s health solutions, including a variety of portable X-ray systems, a complete DR suite, a new generation of flat panel detectors and now a full field digital mammography solution with digital breast tomosynthesis.

Fujifilm’s ASPIRE Cristalle mammography system with DBT is available for purchase and shipping in Canada, beginning on October 1st, 2021. For more information about FUJIFILM Canada, please visit: https://www.fujifilm.com/ca/en/healthcare/medical-imaging/mammography/aspire-cristalle

About Fujifilm

FUJIFILM Canada Inc. sells and markets a range of Fujifilm products and services across a broad range of industries including consumer and commercial photo imaging, and industrial products. The Imaging Division comprises instax(r), instant cameras and film, one-time cameras, photographic paper and digital printing equipment. The Medical Systems Division offers solutions for diagnostic imaging technologies. Fujifilm’s industrial products include products for pressure measurement film and non-destructive testing. For more information, please visit http://www.Fujifilm.ca

FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its core technologies are used in healthcare, high-functional materials, document solutions, and imaging products. Its extensive portfolio of optical, electronic, chemical and mechanical technologies is the basis for these products and services. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed responsible corporate citizenship and environmental stewardship. For more information, please visit: http://www.fujifilmholdings.com

About Christie Innomed

Christie Innomed develops, distributes, integrates and supports innovative medical equipment and software solutions. Our team of 200 experts provides clinical expertise to support our 1,500 healthcare sector clients from coast to coast. We bring the best in healthcare innovation and technology to Canada through exclusive international partners. Our IT solutions are industry leaders and help improve clinical decision-making for better patient care.

As Canada’s leading multi-vendor imaging and biomedical services provider, we are a single point of contact that effectively addresses your needs to reduce clinical risk while improving financial performance. Our 65 years in the industry is a testimony of our commitment to excellence.

Contact Data

Marissa Confredo Fujifilm marissa.confredo@fujifilm.com Michele Gagnon Christie Innomed (450) 472-9120 x2228 mgagnon@christieinnomed.com

For more dWeb.News Business News: https://dweb.news/news-sections/business-news/

The post BUSINESS: Fujifilm’s Cristalle Digital Mammography System ASPIRE Cristalle Receives Health Canada Medical Device License appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

The post BUSINESS: Fujifilm’s Cristalle Digital Mammography System ASPIRE Cristalle Receives Health Canada Medical Device License appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

dWeb.NewsRead More

Similar Posts